{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Camizestrant",
  "nciThesaurus": {
    "casRegistry": "2222844-89-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.",
    "fdaUniiCode": "JUP57A8EPZ",
    "identifier": "C160603",
    "preferredName": "Camizestrant",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C2116"
    ],
    "synonyms": [
      "AZ-14066724",
      "AZD 9833",
      "AZD-9833",
      "AZD9833",
      "CAMIZESTRANT",
      "Camizestrant",
      "N-(1-(3-Fluoropropyl)-3-azetidinyl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine",
      "SERD AZD9833",
      "Selective Estrogen Receptor Degrader AZD9833"
    ]
  }
}